Adempas and Gallbladder attack - a phase IV clinical study of FDA data
Summary:
Gallbladder attack is reported as a side effect among people who take Adempas (riociguat), especially for people who are female, 60+ old, also take Dilaudid, and have Primary pulmonary hypertension.
The phase IV clinical study analyzes which people have Gallbladder attack when taking Adempas. It is created by eHealthMe based on reports of 29,726 people who have side effects when taking Adempas from the FDA, and is updated regularly.
What is Adempas?
Adempas has active ingredients of riociguat. eHealthMe is studying from 29,740 Adempas users. Check the latest studies of Adempas.
What is Gallbladder attack?
Gallbladder attack (gallstones, gallbladder disease and gallbladder pain) is found to be associated with 604 drugs and 985 conditions by eHealthMe. Check the latest studies of Gallbladder attack.
29,726 people reported to have side effects when taking Adempas.
Among them, 7 people (0.02%) have Gallbladder attack.

Among these 7 people:
What is the gender of people who have Gallbladder attack when taking Adempas? *
- female: 66.67 %
- male: 33.33 %
What is the age of people who have Gallbladder attack when taking Adempas? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
What are other drugs people take besides Adempas? *
- Tyvaso Dpi: 2 people, 28.57%
- Potassium: 2 people, 28.57%
- Phenergan: 2 people, 28.57%
- Lasix: 2 people, 28.57%
- Eliquis: 2 people, 28.57%
- Dilaudid: 2 people, 28.57%
- Veletri: 1 person, 14.29%
- Uptravi: 1 person, 14.29%
- Sertraline: 1 person, 14.29%
- Opsumit: 1 person, 14.29%
What are other side effects people have besides Gallbladder attack? *
- Hypotension (abnormally low blood pressure): 5 people, 71.43%
- Weight Decreased: 4 people, 57.14%
- Dizziness: 4 people, 57.14%
- Gallstones (stone formation by bile component): 4 people, 57.14%
- Nausea (feeling of having an urge to vomit): 4 people, 57.14%
- Headache (pain in head): 4 people, 57.14%
- Cardiac Failure Congestive: 2 people, 28.57%
- Constipation: 2 people, 28.57%
- Cough: 2 people, 28.57%
- Head Injury: 2 people, 28.57%
What are the existing conditions these people have? *
- Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 6 people, 85.71%
- Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 14.29%
* Approximation only. Some reports may have incomplete information.
Do you take Adempas and have Gallbladder attack?
- Check whether Gallbladder attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Adempas:
- Adempas (29,740 reports)
Gallbladder attack treatments and more:
- Gallbladder attack (4,101 reports)
How severe was Gallbladder attack and when was it recovered:
Expand to all the drugs that have ingredients of riociguat:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Adempas:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Gallbladder attack:
- Gallbladder attack (604 drugs)
Browse all the conditions that are associated with Gallbladder attack:
- Gallbladder attack (985 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on riociguat (the active ingredients of Adempas) and Adempas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Lantus cause Anoxic Encephalopathy? - 4 seconds ago
- Could Onglyza cause Back Pain? - 5 seconds ago
- Drug interactions of Nitrol and Citalopram Hydrobromide - 7 seconds ago
- Pindolol vs. Inderal La, side effect and effectiveness comparison - 8 seconds ago
- Hyperlipidaemia and General Physical Health Deterioration - 9 seconds ago
- Could Aprepitant cause Barrett'S Oesophagus? - 9 seconds ago
- Could Valsartan cause Urine Output Increased? - 22 seconds ago
- Could Naproxen cause Radiculitis? - 23 seconds ago
- Could Lotrel cause Fungal Infection? - 26 seconds ago
- Could Ambien cause Psychomotor Skills Impaired? - 27 seconds ago